MSLE

Satellos Bioscience Inc

• NASDAQ·10h ago

  Satellos Changes BASECAMP Endpoint After FDA Feedback; Data Expected In Q1 2027

• TipRanks·14h ago

  Satellos Changes Primary Endpoint in Pediatric Duchenne Trial After FDA Feedback

• TipRanks·1d ago

  Satellos to Update Investors on BASECAMP DMD Study Strategy

• TipRanks·10/21 11:27

  Satellos Bioscience to Court Investors at November Healthcare Conferences

• TipRanks·10/08 20:55

  Satellos management to meet with Cantor

• TipRanks·10/08 13:10

  Craig-Hallum initiates Satellos with a Buy ahead of BASECAMP data

• TipRanks·10/08 11:36

  Satellos initiated with a Buy at Craig-Hallum

• TipRanks·10/05 11:28

  Satellos Secures Long-Term U.S. Patent Protection for Lead Drug Forazapadin

• TipRanks·10/01 00:35

  Analyst Reiterates Buy on Satellos Bioscience, Maintains Unchanged $22 Price Target Amid Steady DMD Trial Progress

• NASDAQ·09/30 12:23

  Satellos Completes Enrollment In Phase 2 Forazapadin Trial For DMD

• TipRanks·09/30 11:15

  Satellos announces enrollment completed for BASECAMP

• TipRanks·09/25 11:10

  Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Kyverna Therapeutics, Inc. (KYTX)

• TipRanks·09/24 15:25

  Satellos Bioscience: Regulatory Advances and Upcoming DMD Readouts Support Buy Rating, Price Target Maintained at $22

• TipRanks·09/24 11:40

  Satellos Wins FDA Green Light for FSHD Trial and Secures Up to US$5 Million in Non-Dilutive Funding

• NASDAQ·09/24 11:29

  Satellos Gets FDA Clearance For Forazapadin In FSHD; Phase 2 Study Planned